Company intelligence / Profile preview

CSRC Group

Ownership: Private
Employees: ~1419
Development stage: Other

Overview

CSRC Group, through its subsidiary Synpac, licensed the enzyme replacement therapy for Pompe disease to Sanofi Genzyme, resulting in the commercial drugs Lumizyme and Myozyme. The group’s biotech division invests in pharmaceutical R&D and collaborates with hospitals and research units to develop new prescription drugs. The core business remains carbon black manufacturing, but the group maintains an active presence in life sciences through licensing and investment activities.

Therapeutic areas: Rare Diseases
Modalities: Enzyme replacement therapy
Industry: Chemicals & Materials

Partnerships

Sanofi Genzyme (licensee of Pompe drug technology/Lumizyme-Myozyme)Collaborations with hospitals and academic research units for new drug development

Beyond the preview

Go deeper on CSRC Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CSRC Group.

Explore the full profile